| 11.19 1.9 (20.45%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.19 |
1-year : | 15.41 |
| Resists | First : | 11.3 |
Second : | 13.19 |
| Pivot price | 7.75 |
|||
| Supports | First : | 8.03 |
Second : | 6.01 |
| MAs | MA(5) : | 9.1 |
MA(20) : | 7.69 |
| MA(100) : | 9.95 |
MA(250) : | 8.33 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 88.4 |
D(3) : | 85.5 |
| RSI | RSI(14): 69.1 |
|||
| 52-week | High : | 20 | Low : | 5.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PASG ] has closed Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.31 - 11.36 | 11.36 - 11.39 |
| Low: | 8.87 - 8.92 | 8.92 - 8.95 |
| Close: | 11.11 - 11.19 | 11.19 - 11.26 |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Tue, 07 Apr 2026
Passage Bio (PASG) 2026 proxy details director elections, KPMG ratification and executive pay - Stock Titan
Tue, 31 Mar 2026
Oppenheimer Initiates Coverage on PASG with Outperform Rating | - GuruFocus
Tue, 31 Mar 2026
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Wed, 18 Mar 2026
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
Wed, 11 Mar 2026
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Wed, 04 Mar 2026
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 51.6 (%) |
| Shares Short | 98 (K) |
| Shares Short P.Month | 92 (K) |
| EPS | -14.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -113.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|